{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:54:54Z","timestamp":1790934894039,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Only a subset of individuals meeting National Comprehensive Cancer Network (NCCN) guidelines for genetic screening of hereditary cancers are being offered testing. A community-based screening program has the potential to expand access, identify critical screening opportunities among those testing positive, and have potential downstream clinical effects.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We conducted a retrospective review of women who underwent mammography and genetic testing at a community hospital between August 2020 and May 2023. For those testing positive for a pathogenic\/likely pathogenic (P\/LP) variant, potential cancer screening and surgical recommendations were identified utilizing NCCN guidelines.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>A total of 14,192 women were screened, with 3224 (23%) meeting NCCN criteria. Of these patients, 50.3% opted for testing and 7.6% were found to have P\/LP variants, encompassing 18 different genes. The genes with the highest prevalence of P\/PV variants included CHEK2 (26%), MUTYH (21%), BRCA2 (8%), APC I1370K (8%), and Lynch Syndrome-associated (7%). Among those positive for a P\/LP variant, individuals were identified to be at an increased risk for at least one form of cancer, including breast (52%), colon (45%), ovarian (31%), pancreas (28%), melanoma (20%), endometrial (11%), urologic (7%), and stomach\/small bowel (7%), leading to a potential change in screening and risk-reducing surgery recommendations. For the total population tested, 5.3% of women qualified for MRI or earlier mammograms, and 3.4% needed earlier or more frequent screening colonoscopies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>These findings suggest that a community-based genetic program can identify individuals at increased cancer risk who might otherwise remain undetected. These results provide opportunities to reduce morbidity\/mortality through increased screening and risk-reducing procedures.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1245\/s10434-025-17820-w","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T15:50:50Z","timestamp":1754495450000},"page":"9041-9049","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Identification of Patients at Elevated Cancer Risk through a Community-Based Genetic Testing Program"],"prefix":"10.1245","volume":"32","author":[{"given":"Danielle","family":"Brabender","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie O.","family":"Culver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob G.","family":"Comeaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Date","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Woodworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"17820_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1200\/JCO.18.01631","volume":"37","author":"PD Beitsch","year":"2019","unstructured":"Beitsch PD, Whitworth PW, Hughes K, et al. Underdiagnosis of hereditary breast cancer: are genetic testing guidelines a tool or an obstacle? J Clin Oncol. 2019;37:453\u201360.","journal-title":"J Clin Oncol."},{"issue":"7","key":"17820_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.6004\/jadpro.2021.12.7.3","volume":"12","author":"M Ward","year":"2021","unstructured":"Ward M, Elder B, Habtemariam M. Current testing guidelines: a retrospective analysis of a community-based hereditary cancer program. J Adv Pract Oncol. 2021;12(7):693\u2013701. https:\/\/doi.org\/10.6004\/jadpro.2021.12.7.3.","journal-title":"J Adv Pract Oncol."},{"key":"17820_CR3","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1200\/JCO.18.01854","volume":"37","author":"AW Kurian","year":"2019","unstructured":"Kurian AW, Ward KC, Howlader N, et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019;37:1305\u201315.","journal-title":"J Clin Oncol."},{"key":"17820_CR4","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1097\/COC.0000000000000073","volume":"39","author":"A Stuckey","year":"2016","unstructured":"Stuckey A, Febbraro T, Laprise J, Wilbur JS, Lopes V, Robison K. Adherence patterns to National Comprehensive Cancer Network guidelines for referral of women with breast cancer to genetics professionals. Am J Clin Oncol. 2016;39:363\u20137.","journal-title":"Am J Clin Oncol."},{"key":"17820_CR5","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1245\/s10434-020-09123-z","volume":"28","author":"JJ Alberty-Oller","year":"2021","unstructured":"Alberty-Oller JJ, Weltz S, Santos A, et al. Adherence to NCCN guidelines for genetic testing in breast cancer patients: who are we missing? Ann Surg Oncol. 2021;28:281\u20136.","journal-title":"Ann Surg Oncol."},{"key":"17820_CR6","doi-asserted-by":"publisher","unstructured":"Childers CP, Childers KK, Maggard-Gibbons M, Macinko J. National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer [published erratum appears in J Clin Oncol. 2018 Feb;36(4):432]. J Clin Oncol. 2017 Dec;35(34):3800-3806. https:\/\/doi.org\/10.1200\/JCO.2017.73.6314.","DOI":"10.1200\/JCO.2017.73.6314"},{"issue":"7","key":"17820_CR7","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/jpm12071146","volume":"12","author":"A Mansur","year":"2022","unstructured":"Mansur A, Zhang F, Lu CY. Genetic testing and\/or counseling for colorectal cancer by health insurance type. J Pers Med. 2022;12(7):1146. https:\/\/doi.org\/10.3390\/jpm12071146.","journal-title":"J Pers Med."},{"key":"17820_CR8","doi-asserted-by":"publisher","unstructured":"Culver JO, Freiberg Y, Ricker C, et al. Integration of universal germline genetic testing for all new breast cancer patients. Ann Surg Oncol. Epub 26 Sep 2022. https:\/\/doi.org\/10.1245\/s104 34-022-12595-w.","DOI":"10.1245\/s104"},{"issue":"2","key":"17820_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/jamaoncol.2020.6252","volume":"7","author":"NJ Samadder","year":"2021","unstructured":"Samadder NJ, Riegert-Johnson D, Boardman L, et al. Comparison of universal genetic testing vs guideline-directed targeted testing for patients with hereditary cancer syndrome. JAMA Oncol. 2021;7(2):230\u20137.","journal-title":"JAMA Oncol."},{"key":"17820_CR10","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1245\/s10434-016-5328-7","volume":"23","author":"A Chiba","year":"2016","unstructured":"Chiba A, Hoskin TL, Hallberg EJ, et al. Impact that timing of genetic mutation diagnosis has on surgical decision-making and outcome for BRCA1\/BRCA2 mutation carriers with breast cancer. Ann Surg Oncol. 2016;23:3232\u20138.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"17820_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s13073-023-01174-7","volume":"15","author":"ND Rao","year":"2023","unstructured":"Rao ND, Kaganovsky J, Malouf EA, Coe S, Huey J, Tsinajinne D, et al. Diagnostic yield of genetic screening in a diverse, community-ascertained cohort. Genome Med. 2023;15(1):26.","journal-title":"Genome Med."},{"key":"17820_CR12","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41591-020-0982-5","volume":"26","author":"JJ Grzymski","year":"2020","unstructured":"Grzymski JJ, Elhanan G, Morales Rosado JA, et al. Population genetic screening efficiently identifies carriers of autosomal dominant diseases. Nat Med. 2020;26:1235\u20139.","journal-title":"Nat Med."},{"key":"17820_CR13","doi-asserted-by":"crossref","unstructured":"Dusic EJ, Theoryn T, Wang C, Swisher EM, Bowen DJ; EDGE Study Team. Barriers, interventions, and recommendations: Improving the genetic testing landscape.\u00a0Frontiers in Digital Health. 2022;4:961128.","DOI":"10.3389\/fdgth.2022.961128"},{"issue":"1","key":"17820_CR14","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s12687-018-0364-6","volume":"10","author":"B Harding","year":"2019","unstructured":"Harding B, Webber C, Ruhland L, Dalgarno N, Armour CM, Birtwhistle R, et al. Primary care providers\u2019 lived experiences of genetics in practice. J Commun Genet. 2019;10(1):85\u201393. https:\/\/doi.org\/10.1007\/s12687-018-0364-6.","journal-title":"J Commun. Genet."},{"issue":"11","key":"17820_CR15","first-page":"487","volume":"69","author":"SA Evenson","year":"2016","unstructured":"Evenson SA, Hoyme HE, Haugen-Rogers JE, Larson EA, Puumala SE. Patient and physician perceptions of genetic testing in primary care. S D Med. 2016;69(11):487\u201393.","journal-title":"S D Med."},{"issue":"2","key":"17820_CR16","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s13187-020-01823-0","volume":"37","author":"F Guo","year":"2022","unstructured":"Guo F, Hirth JM, Fuchs EL, Cofie LE, Brown V, Kuo Y-F, et al. Knowledge, attitudes, willingness to pay, and patient preferences about genetic testing and subsequent risk management for cancer prevention. J Cancer Educ. 2022;37(2):362\u20139. https:\/\/doi.org\/10.1007\/s13187-020-01823-0.","journal-title":"J Cancer Educ."},{"key":"17820_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21203\/rs.3.rs-365468\/v1","volume":"11","author":"CL Blomen","year":"2021","unstructured":"Blomen CL, Pott A, Volk AE, Bud\u00e4us L, Witzel I. Communication processes about predictive genetic testing within high-risk breast cancer families: a two-phase study design. Res Square. 2021;11:1\u201310. https:\/\/doi.org\/10.21203\/rs.3.rs-365468\/v1.","journal-title":"Res Square."},{"issue":"8","key":"17820_CR18","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1093\/jnci\/djz009","volume":"111","author":"AM McCarthy","year":"2019","unstructured":"McCarthy AM. Persistent underutilization of BRCA1\/2 testing suggest the need for new approaches to genetic testing delivery. J Natl Cancer Inst. 2019;111(8):751\u20133. https:\/\/doi.org\/10.1093\/jnci\/djz009.","journal-title":"J Natl Cancer Inst."},{"key":"17820_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/EDBK_350292","volume":"42","author":"MK Frey","year":"2022","unstructured":"Frey MK, Finch A, Kulkarni A, Akbari MR, Chapman-Davis E. Genetic testing for all: overcoming disparities in ovarian cancer genetic testing. Am Soc Clin Oncol Educ Book. 2022;42:1\u201312. https:\/\/doi.org\/10.1200\/EDBK_350292.","journal-title":"Am Soc Clin Oncol Educ Book."},{"issue":"10","key":"17820_CR20","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.22874","volume":"3","author":"GF Guzauskas","year":"2020","unstructured":"Guzauskas GF, Garbett S, Zhou Z, Spencer SJ, Smith HS, Hao J, et al. Cost-effectiveness of population-wide genomic screening for hereditary breast and ovarian cancer in the United States. JAMA Netw Open. 2020;3(10):e2022874. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.22874.","journal-title":"JAMA Netw Open."},{"issue":"4","key":"17820_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.37428","volume":"15","author":"JC Jones","year":"2023","unstructured":"Jones JC, Golafshar MA, Coston TW, Rao R, Wysokinska E, Johnson E, et al. Universal genetic testing vs. guideline-directed testing for hereditary cancer syndromes among traditionally underrepresented patients in a community oncology program. Cureus. 2023;15(4):e37428. https:\/\/doi.org\/10.7759\/cureus.37428.","journal-title":"Cureus."},{"issue":"16","key":"17820_CR22","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1002\/cncr.34349","volume":"128","author":"S Knerr","year":"2022","unstructured":"Knerr S, Guo B, Mittendorf KF, Feigelson HS, Gilmore MJ, Jarvik GP. Risk-reducing surgery in unaffected individuals receiving cancer genetic testing in an integrated health care system. Cancer. 2022;128(16):3090\u20138. https:\/\/doi.org\/10.1002\/cncr.34349.","journal-title":"Cancer."},{"issue":"2","key":"17820_CR23","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10549-014-3134-0","volume":"148","author":"X Chai","year":"2014","unstructured":"Chai X, Friebel TM, Singer CF, et al. Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2014;148(2):397\u2013406.","journal-title":"Breast Cancer Res Treat."},{"issue":"2","key":"17820_CR24","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1136\/jmedgenet-2020-107356","volume":"59","author":"R Marcinkute","year":"2022","unstructured":"Marcinkute R, Woodward ER, Gandhi A, et al. Uptake and efficacy of bilateral risk reducing surgery in unaffected female BRCA1 and BRCA2 carriers. J Med Genet. 2022;59(2):133\u201340.","journal-title":"J Med Genet."},{"issue":"4","key":"17820_CR25","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3122\/jabfm.2021.04.200381","volume":"34","author":"SP David","year":"2021","unstructured":"David SP, Dunnenberger HM, Ali R, et al. Implementing primary care mediated population genetic screening within an integrated health system. J Am Board Fam Med. 2021;34(4):861\u20135.","journal-title":"J Am Board Fam Med."},{"issue":"7","key":"17820_CR26","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.gim.2022.03.007","volume":"24","author":"F Angelo","year":"2022","unstructured":"Angelo F, Veenstra D, Knerr S, Devine B. Prevalence and prediction of medical distrust in a diverse medical genomic research sample. Genet Med. 2022;24(7):1459\u201367.","journal-title":"Genet Med."},{"issue":"1","key":"17820_CR27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13073-021-00832-y","volume":"13","author":"NS Abul-Husn","year":"2021","unstructured":"Abul-Husn NS, Soper ER, Braganza GT, et al. Implementing genomic screening in diverse populations. Genome Med. 2021;13(1):17.","journal-title":"Genome Med."},{"issue":"9","key":"17820_CR28","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/gim.2015.187","volume":"18","author":"DJ Carey","year":"2016","unstructured":"Carey DJ, Fetterolf SN, Davis FD, et al. The Geisinger MyCode community health initiative: an electronic health record-linked biobank for precision medicine research. Genet Med. 2016;18(9):906\u201313.","journal-title":"Genet Med."},{"key":"17820_CR29","unstructured":"Ambry Genetics. Cancer care. Available at: https:\/\/www.ambrygen.com\/partners\/care\/cancer. Accessed Sep 2024."},{"key":"17820_CR30","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Genetic\/Familial High Risk Assessment: Breast, Ovarian, and Pancreatic Version 3.2023. 2023 Feb 13; National Comprehensive Cancer Network."},{"key":"17820_CR31","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Genetic\/Familial High Risk Assessment: Colorectal Version 1.2023. 2023 May 30; National Comprehensive Cancer Network."},{"issue":"2","key":"17820_CR32","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1034\/j.1399-0004.2002.610205.x","volume":"61","author":"M Cappelli","year":"2002","unstructured":"Cappelli M, Hunter AG, Stern H, Humphreys L, Van Houten L, O\u2019Rourke K, Viertelhausen S, Perras H, Lagarde AE. Participation rates of Ashkenazi Jews in a colon cancer community-based screening\/prevention study. Clin Genet. 2002;61(2):104\u201314. https:\/\/doi.org\/10.1034\/j.1399-0004.2002.610205.x.","journal-title":"Clin Genet."},{"key":"17820_CR33","doi-asserted-by":"publisher","unstructured":"Zhang L, Bao Y, Riaz M, Tiller J, Liew D, Zhuang X, Amor DJ, Huq A, Petelin L, Nelson M, James PA, Winship I, McNeil JJ, Lacaze P. Population genomic screening of all young adults in a health-care system: a cost-effectiveness analysis [published erratum appears in Genet Med. 2019 Sep;21(9):2162-2163]. Genet Med. 2019 Sep;21(9):1958-1968. https:\/\/doi.org\/10.1038\/s41436-019-0457-6.","DOI":"10.1038\/s41436-019-0457-6"},{"issue":"1","key":"17820_CR34","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1080\/13696998.2022.2152233","volume":"26","author":"S Teppala","year":"2023","unstructured":"Teppala S, Hodgkinson B, Hayes S, Scuffham P, Tuffaha H. A review of the cost-effectiveness of genetic testing for germline variants in familial cancer. J Med Econ. 2023;26(1):19\u201333.","journal-title":"J Med Econ."},{"issue":"16","key":"17820_CR35","doi-asserted-by":"publisher","first-page":"8330","DOI":"10.3390\/ijerph18168330","volume":"18","author":"AR Ramdzan","year":"2021","unstructured":"Ramdzan AR, Manaf MRA, Aizuddin AN, Latiff ZA, Teik KW, Ch\u2019ng GS, Ganasegeran K, Aljunid SM. Cost-effectiveness of colorectal cancer genetic testing. Int J Environ Res Public Health. 2021;18(16):8330.","journal-title":"Int J Environ Res Public Health."},{"issue":"12","key":"17820_CR36","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1200\/OP.23.00817","volume":"20","author":"CB Mauer Hall","year":"2024","unstructured":"Mauer Hall CB, Reys BD, Gemmell AP, Campbell CL, Pirzadeh-Miller SM. Downstream revenue generated by patients with hereditary cancer in the multigene panel testing era. JCO Oncol Pract. 2024;20(12):1695\u2013704.","journal-title":"JCO Oncol Pract."},{"issue":"1","key":"17820_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.gim.2023.100980","volume":"26","author":"JO Culver","year":"2024","unstructured":"Culver JO, Bertsch NL, Kurz RN, Cheng LL, Pritzlaff M, Rao SK, Stasi SM, Stave CD, Sharaf RN. Systematic evidence review and meta-analysis of outcomes associated with cancer genetic counseling. Genet Med. 2024;26(1):100980. https:\/\/doi.org\/10.1016\/j.gim.2023.100980.","journal-title":"Genet Med."},{"issue":"11","key":"17820_CR38","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1001\/jamaoncol.2023.3748","volume":"9","author":"EM Swisher","year":"2023","unstructured":"Swisher EM, Rayes N, Bowen D, Peterson CB, Norquist BM, Coffin T, et al. Remotely delivered cancer genetic testing in the making genetic testing accessible (MAGENTA) trial: a randomized clinical trial. JAMA Oncol. 2023;9(11):1547\u201355.","journal-title":"JAMA Oncol."},{"issue":"1","key":"17820_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.cll.2019.11.005","volume":"40","author":"LM Petersen","year":"2020","unstructured":"Petersen LM, Lefferts JA. Lessons learned from direct-to-consumer genetic testing. Clin Laborat Med. 2020;40(1):83\u201392. https:\/\/doi.org\/10.1016\/j.cll.2019.11.005.","journal-title":"Clin Laborat Med."},{"issue":"11","key":"17820_CR40","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1001\/jamaoncol.2022.4071","volume":"8","author":"BL Bychkovsky","year":"2022","unstructured":"Bychkovsky BL, Agaoglu NB, Horton C, et al. Differences in cancer phenotypes among frequent CHEK2 variants and implications for clinical care-checking CHEK2. JAMA Oncol. 2022;8(11):1598\u2013606. https:\/\/doi.org\/10.1001\/jamaoncol.2022.4071.","journal-title":"JAMA Oncol."},{"key":"17820_CR41","unstructured":"National Comprehensive Cancer Network. Colon Cancer (Version 3.2024). NCCN Clinical Practice Guidelines in Oncology. Published June 2024."},{"key":"17820_CR42","unstructured":"National Comprehensive Cancer Network. Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 1.2025). NCCN Clinical Practice Guidelines in Oncology. Published November 15, 2024."},{"issue":"5","key":"17820_CR43","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1056\/NEJMoa2005936","volume":"384","author":"C Hu","year":"2021","unstructured":"Hu C, Hart SN, Gnanaolivu R, et al. A population-based study of genes previously implicated in breast cancer. N Engl J Med. 2021;384(5):440\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2005936.","journal-title":"N Engl J Med."},{"key":"17820_CR44","doi-asserted-by":"publisher","unstructured":"Board of Directors of the American College of Medical Genetics and Genomics. Management of individuals with germline pathogenic\/likely pathogenic variants in the SDHB gene: a practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2023;25(9):100883. https:\/\/doi.org\/10.1016\/j.gim.2023.100883.","DOI":"10.1016\/j.gim.2023.100883"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17820-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-025-17820-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-025-17820-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:41:13Z","timestamp":1760715673000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-025-17820-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["17820"],"URL":"https:\/\/doi.org\/10.1245\/s10434-025-17820-w","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,6]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Amanda Woodworth has been a one-time paid consultant for Ambry Genetics at their midyear meeting 11 July 23. Danielle Brabender, Emily Siegel, Julie O. Culver, Jacob G. Comeaux, and Anjali Date have no conflicts of interest to declare that may be relevant to the contents of this study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"This study received approval from the Health Sciences Institutional Review Board at the University of Southern California.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}